Halozyme Therapeutics (NASDAQ:HALO) Earnings Information
Halozyme Therapeutics last announced its quarterly earnings results on February 23rd, 2021. The biopharmaceutical company reported $0.50 earnings per share for the quarter, missing the consensus estimate of $0.56 by $0.06. The business had revenue of $121.70 million for the quarter, compared to analyst estimates of $120.75 million. Its revenue was up 126.6% on a year-over-year basis. Halozyme Therapeutics has generated ($0.50) earnings per share over the last year and currently has a price-to-earnings ratio of 255.7. Halozyme Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 10th, 2021 based off prior year's report dates.
Halozyme Therapeutics Earnings Estimates and Actuals by Quarter
The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.
Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates
2021 EPS Consensus Estimate: $1.52
2022 EPS Consensus Estimate: $2.76
Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)